直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Statistics Show a Strong Interest in Challenging Patents at USPTO

December 11, 2013

Authored and Edited by Timothy P. McAnulty; Jeffrey A. Berkowitz

Statistics-Show-a-Strong-Interest-in-Challenging-Patents-at-USPTO

The USPTO recently published updated statistics for filings under the AIA’s new post-grant procedures. As of November 2013, just 14 months after the new post grant challenges went into effect, the USPTO has received over 700 total petitions. The vast majority of them are for inter partes review (IPR), over 600 petitions, although there continues to be a steady filing of petitions for covered business method patents. Of note, 22 covered business method (CBM) reviews were filed in fiscal year 2014 alone. This is already about half of the total number of CBM requests filed for all of fiscal year 2013.

Over 70% of post grant challenges concern electrical/computer patents. Requests in mechanical fields are a distant second at only about 15% of the total filings. Requests for chemical and bio/pharma patents represent about 8% and 6% of the total filings, respectively. Interestingly, there have been 6 IPR petitions filed against design patents.

After a challenger files its petition for either an IPR or CBM, the patent owner has the option of filing a preliminary response for the Board to consider before deciding if it will institute a proceeding. Patent owners are filing preliminary responses to only about half of the IPR and CBM requests. In 82 cases, the patent owner waived its right to file a Preliminary Response, effectively expediting the proceeding.

So far, the Board has issued 256 decisions on whether or not to institute a trial. It has instituted a total of 210 trials, has denied 36 petitions, and has joined 10 petitions to other trials. Considering IPR and CBM petitions together, the Board is instituting trials about 85% of the time. For instituted trials, there have been 57 disposals, including 52 settlements, 2 requests for adverse judgment, 1 dismissal, and 2 written final decisions by the Board.

Additional statistical information about filings under these AIA provisions is available at: http://www.uspto.gov/ip/boards/bpai/stats/aia_statistics_11_07_2013.pdf.

 

Tags

AIA statistics

Related Practices

Design Rights

Contacts

Timothy P. McAnulty
Partner
Washington, DC
+1 202 408 4348
Email
Jeffrey A. Berkowitz
Partner
Reston, VA
+1 571 203 2710
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Virtual Seminar

Patent "Basics" Seminar

May 19, 2026

Virtual

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP